AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19808454 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (group 1, 25 patients)
Number of subjects: 50
Study 19808454 — intervention group
Group type: COMPARATOR
Intervention: Conscious sedation with fentanyl or midazolam (group 2, 25 patients)
Number of subjects: 50
Study 19808454 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (group 1)
Number of subjects: 50
Study 19808454 — intervention group
Group type: COMPARATOR
Intervention: Conscious sedation (group 2)
Number of subjects: 50
Study 17339566 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 611
Study 17339566 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 611
Study 17339566 — intervention group
Group type: COMPARATOR
Intervention: MT
Number of subjects: 611
Study 14769080 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterarguing
Number of subjects: 0
Study 14769080 — intervention group
Group type: COMPARATOR
Intervention: Undirected thinking
Number of subjects: 0
Study 14769080 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed counterarguing
Number of subjects: 0
Study 11800062 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg combined with hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 217
Study 11800062 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 217
Study 11800062 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 217
Study 10082603 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue engineering materials (e.g., Apligraf, Integra)
Number of subjects: 0
Study 10082603 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric wound dressings (e.g., Tegaderm, Opsite)
Number of subjects: 0
Study 10082603 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal replacements (e.g., reconstituted collagen and chondroitan sulfate)
Number of subjects: 0
Study 8151608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily after six weeks
Number of subjects: 13
Study 8151608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily after ten days
Number of subjects: 13
Study 3340420 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine injection for myofascial trigger points
Number of subjects: 10
Study 3340420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous naloxone (10 mg)
Number of subjects: 10
Study 3340420 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 10
Study 29650774 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 0
Study 29650774 — intervention group
Group type: COMPARATOR
Intervention: PRPF31(+/‐) knockout mice
Number of subjects: 0
Study 27247177 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate (PP) 39-234 mg
Number of subjects: 311
Study 27247177 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol Decanoate (HD) 25-200 mg
Number of subjects: 311
Study 25896862 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided treatment strategy
Number of subjects: 200
Study 25896862 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment strategy
Number of subjects: 200
Study 23193181 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 24
Study 23193181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21041965 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee exercise group (22 females)
Number of subjects: 70
Study 21041965 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee and hip exercise group (23 females)
Number of subjects: 70
Study 21041965 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 females, no treatment)
Number of subjects: 70
Study 21041965 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-limb single hop test (both intervention groups)
Number of subjects: 70
Study 17391562 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin A (400,000 IU)
Number of subjects: 564
Study 17391562 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant vitamin A (100,000 IU)
Number of subjects: 564
Study 17391562 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both mothers and infants)
Number of subjects: 564
Study 15536230 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (96 mg/d)
Number of subjects: 701
Study 15536230 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (192 mg/d)
Number of subjects: 701
Study 15536230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study 11437473 — intervention group
Group type: EXPERIMENTAL
Intervention: NN703 (tabimorelin) 1.71 mg/kg
Number of subjects: 4
Study 11437473 — intervention group
Group type: EXPERIMENTAL
Intervention: NN703 (tabimorelin) 3.0 mg/kg
Number of subjects: 4
Study 11437473 — intervention group
Group type: EXPERIMENTAL
Intervention: NN703 (tabimorelin) 4.5 mg/kg
Number of subjects: 4
Study 11437473 — intervention group
Group type: EXPERIMENTAL
Intervention: NN703 (tabimorelin) 6.86 mg/kg
Number of subjects: 4
Study 11437473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 9541440 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with intraoperative 0.2mg/ml MMC
Number of subjects: 28
Study 9541440 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with intraoperative 0.4mg/ml MMC
Number of subjects: 28
Study 9541440 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy alone
Number of subjects: 28
Study 7527100 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 0.5 mg
Number of subjects: 12
Study 7527100 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg
Number of subjects: 12
Study 7527100 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 4 mg
Number of subjects: 12
Study 7527100 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (0.5-4 mg range)
Number of subjects: 12
Study 7527100 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 12
Study 7527100 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolaprilat
Number of subjects: 12
Study 3338365 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide and cimetidine
Number of subjects: 20
Study 3338365 — intervention group
Group type: COMPARATOR
Intervention: placebo and cimetidine
Number of subjects: 20
Study 4821036 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation therapy
Number of subjects: 18
Study 4821036 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study 29477665 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib 960 mg tablets twice daily for 52 weeks
Number of subjects: 498
Study 29477665 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 498
Study 27689427 — intervention group
Group type: EXPERIMENTAL
Intervention: EXPECT questionnaire (18-item draft)
Number of subjects: 322
Study 27689427 — intervention group
Group type: EXPERIMENTAL
Intervention: Short form of the EXPECT questionnaire (3-item)
Number of subjects: 322
Study 25795646 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg/day
Number of subjects: 920
Study 25795646 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg/day
Number of subjects: 920
Study 25795646 — intervention group
Group type: COMPARATOR
Intervention: Placebo to Fingolimod 0.5 mg/day
Number of subjects: 920
Study 25795646 — intervention group
Group type: COMPARATOR
Intervention: Placebo to Fingolimod 1.25 mg/day
Number of subjects: 920
Study 23764639 — intervention group
Group type: EXPERIMENTAL
Intervention: Full PopART intervention strategy including home-based HIV testing, linkage to care, universal antiretroviral therapy, voluntary medical male circumcision, diagnosis and treatment of STIs, behavioral counseling, and condom distribution.
Number of subjects: 21
Study 23764639 — intervention group
Group type: EXPERIMENTAL
Intervention: PopART intervention strategy
Number of subjects: 21
Study 21940595 — intervention group
Group type: EXPERIMENTAL
Intervention: FR-MDM (fortified rice midday meal with 19 mg Fe)
Number of subjects: 140
Study 21940595 — intervention group
Group type: COMPARATOR
Intervention: UFR-MDM (unfortified rice midday meal)
Number of subjects: 140
Study 21940595 — intervention group
Group type: EXPERIMENTAL
Intervention: FR-MDM
Number of subjects: 140
Study 21940595 — intervention group
Group type: COMPARATOR
Intervention: UFR-MDM
Number of subjects: 140
Study 21940595 — intervention group
Group type: EXPERIMENTAL
Intervention: FR-MDM and UFR-MDM
Number of subjects: 140
Study 19034753 — intervention group
Group type: EXPERIMENTAL
Intervention: SNRI duloxetine
Number of subjects: 130
Study 17211107 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior-posterior electrode position
Number of subjects: 103
Study 17211107 — intervention group
Group type: COMPARATOR
Intervention: Anterior-lateral electrode position
Number of subjects: 103
Study 17211107 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study 15084194 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-stat
Number of subjects: 30
Study 15084194 — intervention group
Group type: COMPARATOR
Intervention: alpha-stat
Number of subjects: 30
Study 11160635 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg/70 kg)
Number of subjects: 9
Study 11160635 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (1.5 mg/70 kg)
Number of subjects: 9
Study 11160635 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (0.75, 1.5, and 3.0 mg/70 kg)
Number of subjects: 9
Study 11160635 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg/70 kg)
Number of subjects: 9
Study 11160635 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and Nicotine
Number of subjects: 9
Study 9637143 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer screening
Number of subjects: 1126
Study 9637143 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Number of subjects: 1126
Study 9637143 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination
Number of subjects: 1126
Study 9637143 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound
Number of subjects: 1126
Study 9637143 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipants
Number of subjects: 1126
Study 8069732 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous erythropoietin (150 U/Kg/wk to 180 U/Kg/wk)
Number of subjects: 65
Study 8069732 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythropoietin (75 U/Kg/wk to 90 U/Kg/wk)
Number of subjects: 65
Study 8069732 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous erythropoietin (for CAPD patients)
Number of subjects: 65
Study 8069732 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous and intravenous erythropoietin (various doses)
Number of subjects: 65
Study 8069732 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous erythropoietin
Number of subjects: 65
Study 3056073 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Methylpyrazole 10 mg/kg
Number of subjects: 15
Study 3056073 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Methylpyrazole 20 mg/kg
Number of subjects: 15
Study 3056073 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Methylpyrazole 50 mg/kg
Number of subjects: 15
Study 3056073 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Methylpyrazole 100 mg/kg
Number of subjects: 15
Study 3056073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15660797 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized sensor settings (OSS)
Number of subjects: 54
Study 15660797 — intervention group
Group type: COMPARATOR
Intervention: Default sensor setting (DSS)
Number of subjects: 54
Study 31238955 — intervention group
Group type: EXPERIMENTAL
Intervention: HEALTH intervention
Number of subjects: 504
Study 31238955 — intervention group
Group type: EXPERIMENTAL
Intervention: HEALTH training curriculum
Number of subjects: 504
Study 31238955 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 504
Study 27287389 — intervention group
Group type: EXPERIMENTAL
Intervention: 21mg/day nicotine patch and four brief behavior counseling sessions over 8 weeks
Number of subjects: 525
Study 27287389 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhedonic status (hedonic vs. anhedonic)
Number of subjects: 525
Study 27287389 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhedonia
Number of subjects: 525
Study 27287389 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch therapy
Number of subjects: 525
Study 26323736 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D, n=20; 0.5μgkg(‐1)h(‐1))
Number of subjects: 40
Study 26323736 — intervention group
Group type: COMPARATOR
Intervention: Propofol (Group P, n=20; 3mgkg(‐1)h(‐1))
Number of subjects: 40
Study 23612399 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromidin (ipidacrinum) therapy for 2 months
Number of subjects: 53
Study 23612399 — intervention group
Group type: COMPARATOR
Intervention: Control group (37 people without stroke history)
Number of subjects: 53
Study 21528605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupping for 25-30 min
Number of subjects: 60
Study 21528605 — intervention group
Group type: COMPARATOR
Intervention: Cupping for 15 min
Number of subjects: 60
Study 19307500 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus gemcitabine and erlotinib
Number of subjects: 607
Study 19307500 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine and erlotinib
Number of subjects: 607
Study 16450017 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined folic acid 2.5 mg, vitamin B6 50 mg, and vitamin B12 1 mg daily
Number of subjects: 5522
Study 16450017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5522
Study 14998785 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise after antecedent hypoglycemia in men
Number of subjects: 14
Study 14998785 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise after antecedent hypoglycemia in women
Number of subjects: 14
Study 14998785 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous glucose production (EGP) in men after antecedent hypoglycemia
Number of subjects: 14
Study 14998785 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous glucose production (EGP) in women after antecedent hypoglycemia
Number of subjects: 14
Study 11529805 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based nurse intervention (INT) consisting of 16 home visits from birth to 18 months
Number of subjects: 100
Study 11529805 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 100
Study 9242313 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg single dose)
Number of subjects: 103
Study 9242313 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel (Combantrin)
Number of subjects: 103
Study 8466836 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-operative Logo environment (N = 30)
Number of subjects: 83
Study 8466836 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised Logo environment (N = 24)
Number of subjects: 83
Study 8466836 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment control group (N = 29)
Number of subjects: 83
Study 3552364 — intervention group
Group type: EXPERIMENTAL
Intervention: Actrapid-Monotard
Number of subjects: 18
Study 3552364 — intervention group
Group type: COMPARATOR
Intervention: Actrapid-Protaphane
Number of subjects: 18
Study 30431467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuídalos sexual communication intervention
Number of subjects: 660
Study 30431467 — intervention group
Group type: COMPARATOR
Intervention: Physical activity program (control)
Number of subjects: 660
Study 29035602 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose (1 g/kg body mass)
Number of subjects: 10
Study 29035602 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Amylomaize-7 (1 g/kg body mass)
Number of subjects: 10
Study 29035602 — intervention group
Group type: COMPARATOR
Intervention: Flavored water placebo
Number of subjects: 10
Study 28003294 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative management (NOM) with antibiotic therapy alone
Number of subjects: 220
Study 28003294 — intervention group
Group type: COMPARATOR
Intervention: Operative management with prophylactic antibiotics and appendicectomy
Number of subjects: 220
Study 24107844 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin treatment
Number of subjects: 40
Study 22578337 — intervention group
Group type: EXPERIMENTAL
Intervention: Becaplermin gel (Regranex(®))
Number of subjects: 59
Study 22578337 — intervention group
Group type: COMPARATOR
Intervention: Duoderm Hydrogel™
Number of subjects: 59
Study 19242336 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinsertion ultrasound (US) inspection of the ipsilateral neck (n = 151)
Number of subjects: 300
Study 19242336 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group, n = 149)
Number of subjects: 300
Study 17336967 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable DMPA
Number of subjects: 14
Study 15966757 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg/day
Number of subjects: 12
Study 15966757 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 800 mg/day
Number of subjects: 12
Study 15966757 — intervention group
Group type: COMPARATOR
Intervention: Cocaine 20 mg
Number of subjects: 12
Study 15966757 — intervention group
Group type: COMPARATOR
Intervention: Cocaine 40 mg
Number of subjects: 12
Study 11665349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Duraphat, Colgate‐Palmolive Co.) applied at baseline and after four months
Number of subjects: 142
Study 11665349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no professional fluoride applications)
Number of subjects: 142
Study 11665349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Duraphat, Colgate‐Palmolive Co.)
Number of subjects: 142
Study 9853201 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol plus 150 micrograms desogestrel
Number of subjects: 595
Study 9853201 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol plus 75 micrograms gestodene
Number of subjects: 595
Study 8209393 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional medical practitioners delivering family planning services after training for two years
Number of subjects: 0
Study 8209393 — intervention group
Group type: COMPARATOR
Intervention: Control villages (no traditional medical practitioners involved)
Number of subjects: 0
Study 2556433 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype 1 reassortant vaccine
Number of subjects: 116
Study 2556433 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype 2 reassortant vaccine
Number of subjects: 116
Study 2556433 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype 3 (rhesus rotavirus) vaccine
Number of subjects: 116
Study 2556433 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent preparation (serotypes 1 and 3) vaccine
Number of subjects: 116
Study 2556433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 2556433 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA ELISA
Number of subjects: 116
Study 2556433 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG ELISA
Number of subjects: 116
Study 2556433 — intervention group
Group type: EXPERIMENTAL
Intervention: PRNA
Number of subjects: 116
Study 2556433 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM ELISA
Number of subjects: 116
Study 2556433 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement fixation (CF)
Number of subjects: 116
Study 2556433 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA ELISA and PRNA
Number of subjects: 116
Study 2556433 — intervention group
Group type: EXPERIMENTAL
Intervention: CF
Number of subjects: 116
Study 4826996 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy plus pyloroplasty
Number of subjects: 40
Study 4826996 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective vagotomy without pyloroplasty
Number of subjects: 40
Study 4826996 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of vagotomy
Number of subjects: 40
Study 4826996 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete selective vagotomy
Number of subjects: 40
Study 4826996 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete selective vagotomy
Number of subjects: 40
Study 31455471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Number of subjects: 206
Study 28543302 — intervention group
Group type: EXPERIMENTAL
Intervention: TOBY therapy plus treatment-as-usual (n=41)
Number of subjects: 80
Study 28543302 — intervention group
Group type: COMPARATOR
Intervention: treatment-as-usual (n=39)
Number of subjects: 80
Study 25384463 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape Up+Internet program+incentives (SII)
Number of subjects: 268
Study 25384463 — intervention group
Group type: COMPARATOR
Intervention: Shape Up+Internet behavioral program (SI)
Number of subjects: 268
Study 25384463 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape Up+Internet program+group sessions (SIG)
Number of subjects: 268
Study 24289799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)‐guided needling combined with leukocyte‐depleted (pure) PRP
Number of subjects: 80
Study 24289799 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 80
Study 21236483 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren plus amlodipine (150 mg aliskiren plus 5 mg amlodipine)
Number of subjects: 1254
Study 21236483 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren (150 mg)
Number of subjects: 1254
Study 21236483 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg)
Number of subjects: 1254
Study 21236483 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (300 mg aliskiren plus 10 mg amlodipine)
Number of subjects: 1254
Study 19120336 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation with 0.5% benzyl nicotinate (BN) and 10% fat
Number of subjects: 0
Study 19120336 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation with 0.3% betamethasone valerate (BV) and low fat content
Number of subjects: 0